National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

275 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-28

Study Completion Date

2018-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate clinical positioning between trastuzumab (Herceptin) monotherapy (H group) and combination therapy of trastuzumab and chemotherapy (H+CT group) based on a randomized controlled trial in women over 70 years with human epidermal growth factor receptor type-2 (HER2) positive primary breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)

NCT05036005

Breast Cancer Breast Neoplasms Breast Cancer Female +1 more

UNKNOWN PHASE4

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755

Breast Cancer

NOT_YET_RECRUITING PHASE2

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00054587

Breast Cancer

COMPLETED PHASE3

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

NCT01548677

Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Circulating Tumor Cells

COMPLETED PHASE2

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

NCT01432223

Breast Cancer HER-2 Positive Breast Cancer Effects of Chemotherapy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized, comparative trial of postoperative adjuvant therapies in women with HER2 (human epidermal growth factor receptor type-2)-positive primary breast cancer who are ≥70 years of age that will compare trastuzumab (Herceptin®) monotherapy (H group) and trastuzumab in combination with chemotherapy (H+CT group).

The objectives of this study are as follows.

1. To verify the clinical positioning of trastuzumab monotherapy and combined trastuzumab and chemotherapy as postoperative adjuvant therapies for the treatment of HER2-positive primary breast cancer patients who are ≥70 years of age.
2. To evaluate the safety of trastuzumab monotherapy and combined trastuzumab and chemotherapy in patients who are ≥70 years of age. In particular, to evaluate cardiac disorders that are a characteristic adverse drug reaction of trastuzumab as well as geriatric-related concerns including lipid metabolism, cerebral infarction and cognitive disorders.
3. To evaluate overall survival in patients who are ≥70 years of age using trastuzumab monotherapy or combined trastuzumab and chemotherapy.
4. To evaluate health-related quality of life (HRQOL), cost-effectiveness (utility), and conduct a comprehensive geriatric assessment (CGA) in patients who are ≥70 years of age and using trastuzumab monotherapy or combined trastuzumab and chemotherapy.
5. To establish and expand information networks by the participation of practitioners in clinical trials that are involved in general clinical practice and breast cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

trastuzumab monotherapy

H group (trastuzumab monotherapy group)

* Trastuzumab: 1-year treatment
* Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times

Group Type EXPERIMENTAL

trastuzumab monotherapy

Intervention Type DRUG

trastuzumab and chemotherapy

H+CT group (combination therapy of trastuzumab and chemotherapy)

* Chemotherapy: 12 to 24 weeks
* Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration.

Group Type ACTIVE_COMPARATOR

trastuzumab monotherapy

Intervention Type DRUG

trastuzumab and chemotherapy

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

trastuzumab monotherapy

Intervention Type DRUG

trastuzumab and chemotherapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Herceptin PTX DTX TC AC EC FEC CMF TCb (CBDCA)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically diagnosed as invasive breast cancer and received curative operation for primary breast cancer.
2. Stage: 1 (tumor size \[pT\] \> 0.5 cm), 2A, 2B or 3A/ M0
3. Female between 70 and 80 years old
4. Primary region is HER 2 positive: either 3+ overexpression by IHC or positive by FISH
5. Baseline left ventricular ejection fraction (LVEF) is ≥55% measured by echocardiography or MUGA scan within 4 weeks before registration.
6. PS: 0-1 (ECOG)
7. Sufficient organ function meeting following criteria within 4 weeks before registration:

* Leukocyte ≥2500 mm3
* Neutrophil ≥1500 mm3
* Platelet ≥100 000 mm3
* Serum total bilirubin ≤2.0 x upper limit of normal (ULN)
* ALT (GPT) or AST (GOT) ≤2.5 x ULN
* Serum creatinine ≤2.0 x ULN
* ALP ≤2.5 x ULN
8. No previous endocrine therapy or chemotherapy for breast cancer
9. Signed written informed consent

Exclusion Criteria

1. Active multiple primary cancer (synchronous multiple primary cancer and invasive cancer of other organs)
2. Postoperative histological axillary lymph node metastasis ≥4
3. Axillary lymph node is not histologically evaluated
4. Histologically confirmed positive margin in breast conservation surgery (evaluation of margin status is based on policy of site)
5. History of drug-related allergy which could hinder planned treatment
6. Any history or complication of following cardiac disorders

* History of congestive heart failure, cardiac infarction
* Complication requires treatment such as: ischemic cardiac disorder, arrhythmia, valvular heart disease
7. Poorly controlled hypertension (ex. Systolic arterial pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg)
8. Poorly controlled diabetes
9. Continuous visit to a medial institution is considered difficult due to deterioration of activity of daily living (ADL)
10. Difficult to participate in the trial because of psychiatric disorder or psychiatric symptoms
11. Ineligible to the trial based on decision of an investigator

Minimum Eligible Age

70 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No